Continuous dopaminergic stimulation with parenteral lisuride in complicated Parkinson’s disease

  • S. Bittkau
  • I. R. Klewin
  • I. Suchy
  • H. Przuntek
Part of the Key Topics in Brain Research book series (KEYTOPICS)


The parenteral infusion of lisuride in the treatment of fluctuations in complicated Parkinson’s disease is highly effective. We report about 18 patients, who were treated in our institutions. In our patient-group we observed a significant (p < 0.01) drop in the UPDRS—scores for rigor, akinesia and speech and for OFF-hours (− 30%), tremor remained nearly uneffected. Two deaths following myocardial infarction and pneumonia were not attributable to therapy. 6 patients experienced hallucinations, in 2 of these infusion had to be stopped. In 2 patients with drug-induced mental alterations these phenomena seemed to depend on the ratio of lisuride to levodopa as on the infusion-profile.

This new therapy is time-consuming and needs a highly individual approach, but remains most effective in the treatment of motor fluctuations and of dyskinesias, offering possibly even further insight into the pathogenesis of these phenomena.


Parkinsonian Patient Levodopa Dose Antiparkinsonian Drug Ergot Derivative Hydrogen Maleate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Birkmayer W, Neumayer W (1972) Die Behandlung der DOPA-Psychosen mit L-Tryptophan. Der Nervenarzt 43 /2: 76 – 78PubMedGoogle Scholar
  2. Birkmayer W, Riederer P (1975) Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post mortem findings). J Neural Transm 37: 175 – 182PubMedCrossRefGoogle Scholar
  3. Bittkau S, Przuntek W (1986) Psychosis and the lisuride pump. Lancet ii: 349 (letter)Google Scholar
  4. Bittkau S, Przuntek H (1988) Chronic s. c. lisuride in parkinson’s diseasemotor performance and avoidance of psychiatric side effects. J Neural Transm [Suppl] 27: 35 – 54Google Scholar
  5. Burns RS, Caine DB (1983) Disposition of dopaminergic ergot compounds following oral administration. In: Calne DB, et al (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 153 – 160Google Scholar
  6. Celesia GG, Barr AN (1979) Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 23: 193 – 200CrossRefGoogle Scholar
  7. Critchley P, Grandas Perez F, Quinn N, Coleman R, Parkes D, Marsden CD (1986) Psychosis and the lisuride pump. Lancet ii: 349 (letter)Google Scholar
  8. Critchley PHS, Grandas Perez F, Quinn N, Coleman R, Parkes D, Marsden CD (1988) Continuous subcutaneous lisuride infusions in Parkinson’s disease. J Neural Transm [Suppl] 27: 55 – 60Google Scholar
  9. Fuxe K, Agnati LE, Köhler C, Andersson K, Eneroth P, Calza L, Ögren SO (1983) Heterogenity of brain dopamine systems: Possible discrimination of different types of dopamine systems and receptors by ergot drugs. In: Caine DB, Horowski R, Mc Donald RJ, Wittke W (eds) Lisuride and other dopamine-agonists. Raven Press, New York, pp 11 – 32Google Scholar
  10. Gehlen W, Mü11er J (1974) Zur Therapie der Dopa-Psychosen mit L-Tryptophan. Dtsch Med Wochenschr 99: 457 – 463CrossRefGoogle Scholar
  11. Horowski R, Wachtel H (1976) Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in mice. Eur J Pharmacol 36: 373 – 383PubMedCrossRefGoogle Scholar
  12. Hümpel M, Nieuweboer B, Wendt H, Hasan SH (1981) Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate: effects on plasma prolactin level. Eur J Clin Pharmacol 20: 47 – 51PubMedCrossRefGoogle Scholar
  13. Kehr W (1977) Effect of lisuride and other ergot derivatives on mono-aminergic mechanisms in rat brain. Eur J Pharmacol 41: 261 – 273PubMedCrossRefGoogle Scholar
  14. Klawans HL, Crosset P, Dana N (1975) Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of L-dopa-induced dyskinesias. In: Caine DB, Chase TN, Barbeau A (eds) Advances in Neurology, vol 9. Raven Press, New YorkGoogle Scholar
  15. Lippem S (1976) Psychosis in patient on bromocriptine and levodopa with carbidopa. Lancet ii: 571Google Scholar
  16. McDonald RJ, Horowski R (1983) Lisuride in the treatment of parkinsonism. Eur Neurol 240 – 255Google Scholar
  17. Moskovitz C, Moses H, Klawans HL (1978) Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 135: 669 – 675PubMedGoogle Scholar
  18. Obeso JA, Luquin MR, Martinez Lage JM (1983) Lisuride infusion for Parkinson’s disease. Ann Neurol 14: 134CrossRefGoogle Scholar
  19. Obeso JA, Luquin MR, Martinez-Lage JM (1986) Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson’s disease. Lancet is 467 – 470Google Scholar
  20. Obeso JA, Luquin MR, Vaamonde J, Martinez Lage JM (1988) Subcutaneous administration of lisuride in the treatment of complex motor fluctuations in Parkinson’s disease. J Neural Transm [Suppl] 27: 17 – 25Google Scholar
  21. Parkes JD, Schachter M, Marsden CD, Smith B, Wilson A (1981) Lisuride in parkinsonism. Ann Neurol 9: 48 – 52PubMedCrossRefGoogle Scholar
  22. Ponzio F, Cimino M, Achilli G, Lipartiti M, Perego C, Vantini G, Algeri S(1984) In vivo and in vitro evidence of dopaminergic system down regulation induced by chronic L-dopa. Life Sci 34: 2107–2116CrossRefGoogle Scholar
  23. Przuntek H (1988) Personal communicationGoogle Scholar
  24. Quinn N, Marsden CD, Schachter M, Thompson C, Lang AE, Parkes JD (1983) Intravenous lisuride in extrapyramidal disorders. Raven Press, pp 383 – 393Google Scholar
  25. Reches A, Wagner HR, Jackson-Lewis V, Yablonskaya-Alter E, Fahn S (1984) Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum. Neurology 34: 1208–1212Google Scholar
  26. Riederer P, Reanolds GP, Danielczyk W, Jellinger K, Seeman D (1983) Desensitization of striatal spiperone-binding sites by dopaminergic agonists in Parkinson’s disease. Raven Press, pp 375 – 381Google Scholar
  27. Ruggieri S, Stocchi F, Agnoli A (1986) Lisuride infusion pump for Parkinson’s disease. Lancet ii: 348–349 (letter)Google Scholar
  28. Schneider MB, Murrin LC, Pfeiffer RF, Deupree JD (1984) Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson’s disease. Clin Neuropharm 7 /3: 247 – 257CrossRefGoogle Scholar
  29. Shoulson I, Glaubiger GA, Chase TN (1975) On-off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25: 1144 – 1148PubMedGoogle Scholar
  30. Shukla S, Turner WJ, Newman G (1978) Bromocriptin-related psychosis and treatment. Biol Psychiat 20: 305 – 310Google Scholar
  31. Stocchi F, Ruggieri S, Antonini A, Baronti F, Brughitta G, Bellantuono P, Bravi D, Agnoli A (1988) Subcutaneous lisuride infusion in Parkinson’s disease: clinical results using different modes of administration. J Neural Transm [Suppl] 27: 27 – 33Google Scholar
  32. Suchy I, Krause W (1988) Continuous subcutaneous infusion of lisuride in parkinsonian patients with fluctuations in mobility. De Gruytes (in press)Google Scholar
  33. Sweet RD, Mc Dowell FH, Feigenson JS, Loranger AW, Goodell H (1976) Mental symptoms in Parkinson’s disease during chronic treatment with levodopa. Neurology 26: 30 – 310Google Scholar

Copyright information

© Springer-Verlag/Wien 1989

Authors and Affiliations

  • S. Bittkau
    • 1
  • I. R. Klewin
    • 2
  • I. Suchy
    • 3
  • H. Przuntek
    • 2
  1. 1.Department of NeurologyUniversity of WürzburgFederal Republic of Germany
  2. 2.Department of NeurologySt. Josef University-HospitalBochumFederal Republic of Germany
  3. 3.Department of NeuroendocrinologySchering AGBerlinGermany

Personalised recommendations